Form 4: Alaunos Director Boosts Stake with Stock for Fees

Alaunos Therapeutics director Jaime Vieser acquired 5,340 shares of common stock at $3.16 per share in lieu of board fees, increasing beneficial ownership.

Summary

• Jaime Vieser, a Director of Alaunos Therapeutics, Inc. (TCRT), acquired 5,340 shares of common stock.
• The shares were issued on November 21, 2025, in lieu of board fees.
• The acquisition price per share was $3.16.
• Following this transaction, Jaime Vieser directly beneficially owns 26,499 shares of common stock.
• Additionally, Vieser indirectly beneficially owns 2,100 shares through Reporter's children and 13,503 shares through Brushwood LLC, where Vieser is the Manager.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director's acquisition of shares, especially in lieu of cash, often signals confidence in the company's future performance and aligns management interests with shareholders.

Positives

• A Director acquiring shares, especially in lieu of cash compensation, can signal confidence in the company's future prospects.
• The acquisition increases the director's alignment with shareholder interests.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal of confidence in the company's future, potentially influencing investor sentiment.

Key Dates

Keywords

Alaunos Therapeutics, TCRT, Form 4, Insider Transaction, Director Stock Acquisition, Beneficial Ownership, Equity Compensation